



company with over eight years of experience operating in California's medical cannabis industry.

The agreement details the purchase of all of DTS's assets, extraction equipment and intellectual property, including the Dank Tank brand of extract vaporisers and cartridges. The Issuer intends to bring DTS under the umbrella of a new subsidiary called Alternate Extracts. DTS's management will work with the Issuer to expand production, including relocating operations to a new licensed facility in Adelanto, California. DTS's founder, Keyan Shokraie, will continue to work with the Issuer as the manager of the Adelanto facility.

The Issuer has also signed an agreement with two California cannabis companies, Genesis Integral, Inc. and Professorganix, Inc., to expand, build-out and manage a 60,000 square foot state-licensed facility in Adelanto, California. The Issuer will take a 55% stake in both companies in return for providing equipment and managing operations, including producing wholesale extracts and manufacturing Dank Tank-branded products.

The Issuer intends to begin CO2 extraction immediately following the relocation of DTS's assets and equipment to the Adelanto facility. The Issuer plans to expand production to maximize capacity throughout the 60,000 square feet of already state-licensed space. Leasehold improvements and equipment ordering are underway to expand production rapidly to include distillation, ethanol-based extraction and on-site remediation and decontamination.

#### **Terms of the Agreements**

Under the agreement with Genesis Integral, Inc. and Professorganix, Inc., the Issuer becomes a 55% owner of each company, responsible for managing extraction of hemp and cannabis at two locations in Adelanto, CA. The Issuer will contribute a full extraction laboratory setup of over 125 items and machinery, including specialized shredding, evaporation and distillation equipment valued over \$475,000.

The Issuer will manage full time operations at the facility and employ all staff and technicians. Under the agreement with DTS Lab Services, Inc. The Issuer will acquire 100% of the company's assets, equipment and intellectual property. As consideration for the purchase under the agreement, an initial 250,000 Alternate Health common shares will be issued to DTS along with a \$48,240.84 reimbursement for equipment costs and other expenses. An additional 600,000 common shares will reserved for issuance to DTS as performance-based incentives.

2. Provide a general overview and discussion of the activities of management.

The Issuer's management team has remained focused on its objectives and operational goals, and is on track to attain them; while it continues its efforts to raise market awareness, value, enhance the strength and diversity of the

**Board of Directors and Officers of the Issuer, research and development, and other shareholder outreach initiatives. The Issuer's management also continue to seek new revenue streams and opportunities to develop and increase the stakeholder's value and profitability of the Issuer.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**The Issuer announced that under the terms of the DTS Lab Services acquisition, the Issuer will, upon closing, own and operate the Dank Tank brand of cannabis extract products in California.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**N/A**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**The Issuer announced that the Company has signed an agreement with two California cannabis companies, Genesis Integral, Inc. and Professorganix, Inc., to expand, build-out and manage a 60,000 square foot state-licensed facility in Adelanto, California. The Issuer will take a 55% stake in both companies in return for providing equipment and managing operations, including producing wholesale extracts and manufacturing Dank Tank-branded products.**

**The Company intends to begin CO2 extraction immediately following the relocation of DTS's assets and equipment to the Adelanto facility. The Issuer plans to expand production to maximize capacity throughout the 60,000 square feet of already state-licensed space. Leasehold improvements and equipment ordering are underway to expand production rapidly to include distillation, ethanol-based extraction and on-site remediation and decontamination.**

#### **Terms of the Agreement**

**Under the agreement with Genesis Integral, Inc. and Professorganix, Inc., the Issuer becomes a 55% owner of each company, responsible for managing extraction of hemp and cannabis at two locations in Adelanto, CA. The Issuer will contribute a full extraction laboratory setup of over 125 items and machinery, including specialized shredding, evaporation and distillation equipment valued over \$475,000.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**N/A**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**The Issuer announced that the Company has entered into an agreement for purchase of DTS Lab Services ("DTS"), a leading cannabis extracts company with over eight years of experience operating in California's medical cannabis industry.**

**The agreement details the purchase of all of DTS's assets, extraction equipment and intellectual property, including the Dank Tank brand of extract vaporisers and cartridges. The Issuer intends to bring DTS's management will work with the Company to expand production, including relocating operations to a new licensed facility in Adelanto, California. DTS's founder, Keyan Shokraie, will continue to work with the Company as the manager of the Adelanto facility.**

#### **Terms of the Agreement**

**The Issuer will acquire 100% of the company's assets, equipment and intellectual property. As consideration for the purchase under the agreement, an initial 250,000 Alternate Health common shares will be issued to DTS along with a \$48,240.84 reimbursement for equipment costs and other expenses. An additional 600,000 common shares will reserved for issuance to DTS as performance-based incentives.**

8. Describe the acquisition of new customers or loss of customers.

**N/A**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**N/A**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**The Issuer announced that under the terms of the DTS Lab Services acquisition, DTS's founder, Keyan Shokraie, will work with the Company as the manager of the Adelanto facility.**

- 11. Report on any labour disputes and resolutions of those disputes if applicable.  
**N/A**
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
**N/A**
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
**N/A**
- 14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
N/A	N/A	N/A	N/A

*(1) State aggregate proceeds and intended allocation of proceeds.*

- 15. Provide details of any loans to or by Related Persons.  
**N/A**
- 16. Provide details of any changes in directors, officers or committee members.  
**N/A**
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The political evolution and progression of the legalities surrounding the use of cannabidiol for medical, and cannabis for recreational purposes, will continue to impact and benefit the product development segment of the Issuer’s business. The legalization of cannabis in Canada and California bodes well for the Issuer’s plans for expansion.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 4, 2019.

Scott Holtby  
Name of Director or Senior  
Officer

/s/ "Scott Holtby"  
Signature  
**Vice President**  
**Communications**  
Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer <b>Alternate Health Corp.</b>	For Month End <b>March 2019</b>	Date of Report YY/MM/D <b>19/04/04</b>
Issuer Address <b>400 – 725 Granville Street (Registered and Records Address)</b>		
City/Province/Postal Code <b>Vancouver, BC, V7Y 1G5</b>	Issuer Fax No. ( )	Issuer Telephone No. <b>416-607-5757</b>
Contact Name <b>Scott Holtby</b>	Contact Position <b>Vice President, Communications</b>	Contact Telephone No. <b>416-607-5757</b>
Contact Email Address <b>s.holtby@alternatehealth.ca</b>	Web Site Address <b><u>www.alternatehealth.ca</u></b> <b>www.alternatehealth.com</b>	